Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Tuberculosis

  Free Subscription


Articles published in Am J Respir Crit Care Med

Retrieve available abstracts of 91 articles:
HTML format



Single Articles


    June 2020

  1. Erratum: Tuberculosis Diagnosis in Children Using Xpert Ultra on Different Respiratory Specimens.
    Am J Respir Crit Care Med. 2020;201:1454.
    PubMed    


    May 2020
  2. SCHEUERMANN L, Pei G, Domaszewska T, Zyla J, et al
    Platelets Restrict the Oxidative Burst in Phagocytes and Facilitate Primary Progressive Tuberculosis.
    Am J Respir Crit Care Med. 2020 May 18. doi: 10.1164/rccm.201910-2063.
    PubMed     Abstract available


  3. HIBMA JE, Radtke KK, Dorman SE, Jindani A, et al
    Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
    Am J Respir Crit Care Med. 2020 May 15. doi: 10.1164/rccm.201912-2489.
    PubMed     Abstract available


    April 2020
  4. STOUT JE, Turner NA, Belknap RW, Horsburgh CR, et al
    Reply to: Trials of Tuberculosis Preventive Therapy in People with HIV Infection.
    Am J Respir Crit Care Med. 2020 Apr 13. doi: 10.1164/rccm.202003-0855.
    PubMed    


  5. SWINDELLS S, Hughes M, Chaisson RE
    Trials of Tuberculosis Preventive Therapy in People with HIV Infection.
    Am J Respir Crit Care Med. 2020 Apr 13. doi: 10.1164/rccm.202003-0761.
    PubMed    


    March 2020
  6. DOOLEY KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, et al
    Reply to: High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202002-0359.
    PubMed    


  7. DECROO T, de Jong BC, Piubello A, Souleymane MB, et al
    High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202001-0201.
    PubMed    


    February 2020
  8. WASSERMAN S, Furin J
    Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations.
    Am J Respir Crit Care Med. 2020 Feb 20. doi: 10.1164/rccm.202002-0264.
    PubMed    



  9. Erratum: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2020;201:500-501.
    PubMed    


  10. VERNON A, Bishai W
    Modeling Treatment of Latent Tuberculosis: Shortening the Leap of Faith?
    Am J Respir Crit Care Med. 2020;201:405-406.
    PubMed    


  11. ANDRES S, Merker M, Heyckendorf J, Kalsdorf B, et al
    Bedaquiline-resistant Tuberculosis: Dark Clouds on the Horizon.
    Am J Respir Crit Care Med. 2020 Feb 13. doi: 10.1164/rccm.201909-1819.
    PubMed    


    January 2020
  12. DE JAGER VR, Vanker N, van der Merwe L, van Brakel E, et al
    Optimising beta-lactams Against Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jan 10. doi: 10.1164/rccm.201911-2149.
    PubMed    


  13. VERRALL AJ, Chaidir L, Ruesen C, Apriani L, et al
    Lower BCG Protection Against Mycobacterium tuberculosis Infection After Exposure to Beijing Strains.
    Am J Respir Crit Care Med. 2020 Jan 8. doi: 10.1164/rccm.201912-2349.
    PubMed    


  14. MCSHANE H
    Controlled Human Infection Models - Is it Really Feasible to Give People Tuberculosis?
    Am J Respir Crit Care Med. 2020 Jan 6. doi: 10.1164/rccm.201912-2408.
    PubMed    


    December 2019
  15. GUPTA RK, Lipman M, Jackson C, Sitch A, et al
    Quantitative Interferon Gamma Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis: A Prospective Cohort Study.
    Am J Respir Crit Care Med. 2019 Dec 11. doi: 10.1164/rccm.201905-0969.
    PubMed     Abstract available


  16. ABUBAKAR I, Cobelens FG, Rangaka MX
    The Risk of Falsely Declaring Non-Inferiority of Novel Latent Tuberculosis Treatment in Large Trials.
    Am J Respir Crit Care Med. 2019 Dec 9. doi: 10.1164/rccm.201911-2258.
    PubMed    


    November 2019
  17. NAHID P, Mase SR, Migliori GB, Sotgiu G, et al
    Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2019;200:e93-e142.
    PubMed     Abstract available


  18. OH JY, Min KH, Lee SY, Shim JJ, et al
    Invasive Endobronchial Mycobacterium kansasii Infection.
    Am J Respir Crit Care Med. 2019;200:e143-e144.
    PubMed    


  19. STOUT JE, Turner NA, Belknap RW, Horsburgh CR, et al
    Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.
    Am J Respir Crit Care Med. 2019 Nov 11. doi: 10.1164/rccm.201908-1606.
    PubMed     Abstract available


  20. NARITA M, Sullivan Meissner J, Burzynski J
    Use of Modeling to Inform Tuberculosis Elimination Strategies.
    Am J Respir Crit Care Med. 2019 Nov 7. doi: 10.1164/rccm.201910-2061.
    PubMed    


    October 2019
  21. TEZERA LB, Mansour S, Elkington P
    Reconsidering the Optimal Immune Response to Mycobacterium tuberculosis.
    Am J Respir Crit Care Med. 2019 Oct 28. doi: 10.1164/rccm.201908-1506.
    PubMed     Abstract available


  22. FOREMAN TW, Bucsan AN, Mehra S, Peloquin C, et al
    Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2019 Oct 24. doi: 10.1164/rccm.201903-0646.
    PubMed     Abstract available


  23. MENZIES NA, Parriott A, Shrestha S, Dowdy DW, et al
    Comparative Modelling of Tuberculosis Epidemiology and Policy Outcomes in California.
    Am J Respir Crit Care Med. 2019 Oct 18. doi: 10.1164/rccm.201907-1289.
    PubMed     Abstract available


  24. AUBRY A, Veziris N
    Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections.
    Am J Respir Crit Care Med. 2019;200:1072-1073.
    PubMed    


  25. CHOI HW, Shin JH, Kee SJ, Kwon YS, et al
    Reply to Aubry and Veziris: Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections.
    Am J Respir Crit Care Med. 2019;200:1073-1074.
    PubMed    


    September 2019
  26. SAGAR AS, Dodge DL, Salahuddin M, Warner MT, et al
    Pleural Diseases: Pleurodesis via Indwelling Pleural Catheter, Dasatinib-induced Pleural Effusion, and IL-27 in Tuberculosis Pleural Effusion.
    Am J Respir Crit Care Med. 2019;200:771-773.
    PubMed    


    August 2019
  27. SCHAAF HS, Marais BJ
    The Role of Xpert MTB/RIF Ultra in Diagnosing Pulmonary Tuberculosis in Children.
    Am J Respir Crit Care Med. 2019 Aug 6. doi: 10.1164/rccm.201907-1492.
    PubMed    


  28. ZAR HJ, Workman LJ, Prins M, Bateman LJ, et al
    Tuberculosis Diagnosis in Children Using Xpert Ultra on Different Respiratory Specimens.
    Am J Respir Crit Care Med. 2019 Aug 5. doi: 10.1164/rccm.201904-0772.
    PubMed     Abstract available


    May 2019
  29. NIEDERMAN MS, Nair GB, Matt U, Herold S, et al
    Update in Lung Infections and Tuberculosis 2018.
    Am J Respir Crit Care Med. 2019 May 1. doi: 10.1164/rccm.201903-0606.
    PubMed    


    April 2019
  30. KRANZER K, Kalsdorf B, Heyckendorf J, Andres S, et al
    New WHO Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?
    Am J Respir Crit Care Med. 2019 Apr 26. doi: 10.1164/rccm.201902-0260.
    PubMed    


    March 2019
  31. LEE HS, Kee SJ, Shin JH, Kwon YS, et al
    Xpert MTB/RIF Assay as a Substitute for Smear Microscopy in an Intermediate-Burden Setting.
    Am J Respir Crit Care Med. 2019;199:784-794.
    PubMed     Abstract available


  32. YOON C, Semitala FC, Cattamanchi A
    Reply to Parker: Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities.
    Am J Respir Crit Care Med. 2019;199:665.
    PubMed    


  33. PARKER RA
    Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities.
    Am J Respir Crit Care Med. 2019;199:664.
    PubMed    


    February 2019
  34. GUPTA S, Krug S, Pokkali S, Leanderson T, et al
    Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis.
    Am J Respir Crit Care Med. 2019;199:386-389.
    PubMed    


    January 2019
  35. DHEDA K, Lenders L, Srivastava S, Magombedze G, et al
    Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing.
    Am J Respir Crit Care Med. 2019 Jan 29. doi: 10.1164/rccm.201807-1361.
    PubMed     Abstract available


  36. TE BRAKE LHM, Boeree MJ, Aarnoutse RE
    Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201811-2101.
    PubMed    


  37. VELASQUEZ GE, Brooks MB, Coit JM, Sanchez Garavito E, et al
    Reply to: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201812-2281.
    PubMed    


  38. SULIMAN S, Luabeya AKK, Geldenhuys H, Tameris M, et al
    Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
    Am J Respir Crit Care Med. 2019;199:220-231.
    PubMed     Abstract available


    October 2018
  39. SCHLUGER NW
    Tuberculosis Elimination, Research, and Respect for Persons.
    Am J Respir Crit Care Med. 2018 Oct 19. doi: 10.1164/rccm.201809-1623.
    PubMed    


  40. KESHAVJEE S, Amanullah F, Cattamanchi A, Chaisson R, et al
    Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.
    Am J Respir Crit Care Med. 2018 Oct 18. doi: 10.1164/rccm.201806-1053.
    PubMed     Abstract available


  41. MARTINEZ L, Andrews JR
    Improving Tuberculosis Case Finding in Persons Living with Advanced HIV through New Diagnostic Algorithms.
    Am J Respir Crit Care Med. 2018 Oct 1. doi: 10.1164/rccm.201809-1702.
    PubMed    


    September 2018
  42. YOON C, Semitala FC, Asege L, Katende J, et al
    Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV.
    Am J Respir Crit Care Med. 2018 Sep 7. doi: 10.1164/rccm.201803-0490.
    PubMed     Abstract available


    August 2018
  43. ELKINGTON PT, Bateman AC, Thomas GJ, Ottensmeier CH, et al
    Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.
    Am J Respir Crit Care Med. 2018 Aug 24. doi: 10.1164/rccm.201807-1250.
    PubMed    


    June 2018
  44. VELASQUEZ GE, Brooks MB, Coit JM, Pertinez H, et al
    Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis: A Randomized Controlled Trial.
    Am J Respir Crit Care Med. 2018 Jun 29. doi: 10.1164/rccm.201712-2524.
    PubMed     Abstract available


  45. DHEDA K, Lenders L, Magombedze G, Srivastava S, et al
    Drug Penetration Gradients Associated with Acquired Drug Resistance in Tuberculosis Patients.
    Am J Respir Crit Care Med. 2018 Jun 7. doi: 10.1164/rccm.201711-2333.
    PubMed     Abstract available


    April 2018
  46. MONEDERO-RECUERO I
    Drug-resistant Tuberculosis in Europe. What are We Waiting for?
    Am J Respir Crit Care Med. 2018 Apr 18. doi: 10.1164/rccm.201803-0497.
    PubMed    


  47. SULIMAN S, Thompson E, Sutherland J, Weiner Rd J, et al
    Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis.
    Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201711-2340.
    PubMed     Abstract available


    March 2018
  48. ABUBAKAR I, Gupta RK, Rangaka MX, Lipman M, et al
    Update in Tuberculosis and Non-tuberculous Mycobacteria 2017.
    Am J Respir Crit Care Med. 2018 Mar 14. doi: 10.1164/rccm.201801-0106.
    PubMed    


  49. COX D, Keane J
    Platelets and Tuberculosis: Small Cells, Not So Innocent Bystanders.
    Am J Respir Crit Care Med. 2018 Mar 6. doi: 10.1164/rccm.201802-0279.
    PubMed    


  50. GUNTHER G, van Leth F, Alexandru S, Altet N, et al
    Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries.
    Am J Respir Crit Care Med. 2018 Mar 6. doi: 10.1164/rccm.201710-2141.
    PubMed     Abstract available


    February 2018
  51. SCHWANDER S, Keane J
    Cause or Effect - the Elusive Role of Regulatory T Cells in Tuberculosis.
    Am J Respir Crit Care Med. 2018 Feb 28. doi: 10.1164/rccm.201802-0233.
    PubMed    


  52. FOX KA, Kirwan DE, Whittington AM, Krishnan N, et al
    Platelets Regulate Pulmonary Inflammation and Tissue Destruction in Tuberculosis.
    Am J Respir Crit Care Med. 2018 Feb 8. doi: 10.1164/rccm.201710-2102.
    PubMed     Abstract available


    December 2017
  53. ERNST JD
    Float Like Bacilli, STING Like a B: Type I Interferons in Tuberculosis.
    Am J Respir Crit Care Med. 2017 Dec 20. doi: 10.1164/rccm.201712-2368.
    PubMed    


  54. VARAINE F, Guglielmetti L, Mitnick CD
    Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Am J Respir Crit Care Med. 2017;196:1490-1491.
    PubMed    


  55. VAN LETH F, Gunther G, Hoffmann H, Lange C, et al
    Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Am J Respir Crit Care Med. 2017;196:1489-1490.
    PubMed    


  56. BARRY PM, Lowenthal P, True L, Henry L, et al
    Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Am J Respir Crit Care Med. 2017;196:1488-1489.
    PubMed    


    November 2017
  57. BENARD A, Sakwa I, Schierloh P, Colom A, et al
    B Cells Producing Type I Interferon Modulate Macrophage Polarization in Tuberculosis.
    Am J Respir Crit Care Med. 2017 Nov 21. doi: 10.1164/rccm.201707-1475.
    PubMed     Abstract available


    October 2017
  58. DIVANGAHI M, Behr MA
    Cracking the Vaccine Code in Tuberculosis.
    Am J Respir Crit Care Med. 2017 Oct 18. doi: 10.1164/rccm.201707-1489.
    PubMed     Abstract available


  59. MARTINEZ L, Handel A, Shen Y, Chakraburty S, et al
    A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts.
    Am J Respir Crit Care Med. 2017 Oct 16. doi: 10.1164/rccm.201706-1210.
    PubMed    


  60. DHEDA K
    The Multistep Tuberculosis Diagnostic Cascade. More Than Meets the Eye.
    Am J Respir Crit Care Med. 2017;196:809-811.
    PubMed    


    September 2017
  61. ROSSER A, Pareek M, Turapov O, Wiselka MJ, et al
    Differentially Culturable Tubercule Bacilli are Generated During Non-pulmonary Tuberculosis Infection.
    Am J Respir Crit Care Med. 2017 Sep 7. doi: 10.1164/rccm.201705-1048.
    PubMed    


    August 2017
  62. LEWINSOHN D
    An Expanding Role for Environmental Microbes in Shaping the Immune Response to Infection with Mycobacterium Tuberculosis.
    Am J Respir Crit Care Med. 2017 Aug 25. doi: 10.1164/rccm.201708-1599.
    PubMed    


  63. BANAEI N, Pai M
    Detecting New Mycobacterium Tuberculosis Infection: Time for a More Nuanced Interpretation of QuantiFERON Conversions.
    Am J Respir Crit Care Med. 2017 Aug 1. doi: 10.1164/rccm.201707-1543.
    PubMed    


    July 2017
  64. ABUBAKAR I, Kloprogge F
    End of the Road for Adjunctive Vitamin D Therapy for Pulmonary Tuberculosis?
    Am J Respir Crit Care Med. 2017 Jul 31. doi: 10.1164/rccm.201707-1509.
    PubMed    


  65. SCRIBA TJ, Carpenter C, Carrasco Pro S, Sidney J, et al
    Differential Recognition of Mtb-specific Epitopes as a Function of Tuberculosis Disease History.
    Am J Respir Crit Care Med. 2017 Jul 31. doi: 10.1164/rccm.201706-1208.
    PubMed     Abstract available


  66. CLAYTON K, Polak ME, Woelk CH, Elkington P, et al
    Gene Expression Signatures in Tuberculosis Have Greater Overlap with Autoimmune Than Infectious Diseases.
    Am J Respir Crit Care Med. 2017 Jul 28. doi: 10.1164/rccm.201706-1248.
    PubMed    


  67. NEMES E, Rozot V, Geldenhuys H, Bilek N, et al
    Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of M. tuberculosis Infection.
    Am J Respir Crit Care Med. 2017 Jul 24. doi: 10.1164/rccm.201704-0817.
    PubMed     Abstract available


  68. LESSELLS RJ, Cooke GS, McGrath N, Nicol MP, et al
    Impact of Point-of-care Xpert MTB/RIF on Tuberculosis Treatment Initiation: A Cluster Randomised Trial.
    Am J Respir Crit Care Med. 2017 Jul 20. doi: 10.1164/rccm.201702-0278.
    PubMed     Abstract available


  69. GANMAA D, Munkhzul B, Fawzi W, Spiegelman D, et al
    High-Dose Vitamin D3 During Tuberculosis Treatment in Mongolia: A Randomised Controlled Trial.
    Am J Respir Crit Care Med. 2017 Jul 10. doi: 10.1164/rccm.201705-0936.
    PubMed     Abstract available


    June 2017
  70. METCALFE JZ, Streicher E, Theron G, Colman RE, et al
    Cryptic Micro-heteroresistance Explains M. tuberculosis Phenotypic Resistance.
    Am J Respir Crit Care Med. 2017 Jun 14. doi: 10.1164/rccm.201703-0556.
    PubMed     Abstract available


  71. BURZYNSKI J
    The Use of Modeling to Compare Tuberculosis Dynamics in Four US States.
    Am J Respir Crit Care Med. 2017 Jun 13. doi: 10.1164/rccm.201705-0963.
    PubMed    


  72. GRANDJEAN L
    Investigating the Pathogen Genomic Determinants of Tuberculosis Transmission.
    Am J Respir Crit Care Med. 2017;195:1418-1420.
    PubMed    



  73. Erratum: New Guidelines for the Treatment of Drug-Susceptible Tuberculosis from the American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America: Now Comes the Hard Part.
    Am J Respir Crit Care Med. 2017;195:1540.
    PubMed    


    May 2017
  74. SHRESTHA S, Hill AN, Marks SM, Dowdy DW, et al
    Comparing Drivers and Dynamics of Tuberculosis (TB) in California, Florida, New York and Texas.
    Am J Respir Crit Care Med. 2017 May 5. doi: 10.1164/rccm.201702-0377.
    PubMed     Abstract available


  75. SHAH JA, Musvosvi M, Shey M, Horne DJ, et al
    A Functional TOLLIP Variant is Associated with BCG-Specific Immune Responses and Tuberculosis.
    Am J Respir Crit Care Med. 2017 May 2. doi: 10.1164/rccm.201611-2346.
    PubMed     Abstract available


  76. SCHLUGER NW
    AJRCCM: 100-Year Anniversary. Focus on Tuberculosis.
    Am J Respir Crit Care Med. 2017;195:1112-1114.
    PubMed    


  77. ALLINSON JP, Mackay AJ, Shah PL
    AJRCCM: 100-Year Anniversary. Special Historical Image Section: Tuberculosis Then and Now.
    Am J Respir Crit Care Med. 2017;195:1118-1123.
    PubMed    


  78. VAN ZYL-SMIT RN, Esmail A, Bateman ME, Dawson R, et al
    Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.
    Am J Respir Crit Care Med. 2017;195:1171-1180.
    PubMed     Abstract available


  79. WEDZICHA JA, Brochard LJ, Martinez FD, Martinez FJ, et al
    AJRCCM: 100-Year Anniversary. The Long View and the Fast Lane.
    Am J Respir Crit Care Med. 2017;195:1081-1085.
    PubMed    


  80. SAEKI K, Watanabe S, Waseda Y, Kasahara K, et al
    Endobronchial Lesions of Mycobacterium abscessus Infection in an Immunocompromised Patient.
    Am J Respir Crit Care Med. 2017;195:e37-e38.
    PubMed    


    April 2017
  81. DIACON AH, van Brakel E, Lounis N, Meyvisch P, et al
    Triplicate Sputum Cultures for Efficacy Evaluation of Novel Anti-tuberculosis Regimens.
    Am J Respir Crit Care Med. 2017 Apr 27. doi: 10.1164/rccm.201704-0796.
    PubMed    


    March 2017
  82. DEDICOAT MJ, Gunther G, Crudu V, Duarte R, et al
    Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.
    Am J Respir Crit Care Med. 2017 Mar 21. doi: 10.1164/rccm.201612-2585.
    PubMed    


  83. STOUT JE, Dicks KV
    A Breath of Fresh Air for Patients with Pulmonary Nontuberculous Mycobacterial Infection.
    Am J Respir Crit Care Med. 2017;195:716-717.
    PubMed    


    February 2017

  84. What is Tuberculosis (TB)?
    Am J Respir Crit Care Med. 2017;195:P7-P8.
    PubMed    


    December 2016
  85. NEBENZAHL-GUIMARAES H, van Laarhoven A, Farhat MR, Koeken VA, et al
    Transmissible Mycobacterium tuberculosis Strains Share Genetic Markers and Immune Phenotypes.
    Am J Respir Crit Care Med. 2016 Dec 20. doi: 10.1164/rccm.201605-1042.
    PubMed     Abstract available


  86. DARTOIS V, Saito K, Warrier T, Nathan C, et al
    New Evidence for the Complexity of the Population Structure of Mycobacterium tuberculosis Increases the Diagnostic and Biologic Challenges.
    Am J Respir Crit Care Med. 2016;194:1448-1451.
    PubMed    


    November 2016
  87. LEU JS, Chen ML, Chang SY, Yu SL, et al
    SP110b Controls Host Immunity and Susceptibility to Tuberculosis.
    Am J Respir Crit Care Med. 2016.
    PubMed     Abstract available


  88. HARAUSZ EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, et al
    New/Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis: Practice-Based Recommendations.
    Am J Respir Crit Care Med. 2016.
    PubMed     Abstract available


  89. GUGLIELMETTI L, Le Du D, Frechet-Jachym M, Mitnick C, et al
    Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management.
    Am J Respir Crit Care Med. 2016;194:1170-1171.
    PubMed    


  90. SAUNDERS MJ, Datta S
    Contact Investigation: A Priority for Tuberculosis Control Programs.
    Am J Respir Crit Care Med. 2016;194:1049-1051.
    PubMed    


    October 2016
  91. VARAINE F, Guglielmetti L, Huerga H, Bonnet M, et al
    Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
    Am J Respir Crit Care Med. 2016;194:1028-1029.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: